Vaxcyte (PCVX) recently started dosing participants in a Phase 1 trial of VAX-A1, its investigational Group A Streptococcus vaccine. This development gives investors a fresh clinical milestone to weigh alongside the stock’s recent performance.

The recent VAX-A1 trial news comes as Vaxcyte’s 7-day share price return of 8.39% and 30-day share price return of 8.75% contrast with a softer 90-day share price return. The 1-year total shareholder return of 56.50% points to momentum built over a longer horizon.

If this kind of vaccine progress has your attention, it could be a good moment to scan other healthcare-focused opportunities through our curated list of 40 healthcare AI stocks.

With Vaxcyte shares at $51.44, a value score of 4, and a large gap relative to the $109 analyst target and intrinsic value estimates, investors now face a key question: is there real upside left here, or is the market already pricing in future growth?

Most Popular Narrative: 52.8% Undervalued

With Vaxcyte at $51.44 versus a widely followed fair value of $109, the current price sits well below what the leading narrative implies.

Vaxcyte is a vaccine company focused on developing broader coverage pneumococcal and Group A Strep vaccines for adult and pediatric use.

Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines. If successful, these programs could support future product approvals and create a path to commercial revenue.

Want to see what has to happen for that valuation to stack up? The narrative highlights revenue expansion, margin improvement and a relatively high earnings multiple. Curious which assumptions drive most of the outcome?

Result: Fair Value of $109 (UNDERVALUED)

However, Vaxcyte’s story can shift quickly if late stage VAX-31 data disappoints, or if higher than expected manufacturing costs shorten that cash runway.

Next Steps

With both risks and rewards in play for Vaxcyte, do you want to rely on headlines or your own judgment? Take a closer look at the full picture with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Vaxcyte?

If Vaxcyte has sharpened your focus on quality opportunities, do not stop here; broaden your watchlist now before the next wave of ideas moves without you.

• Target durable businesses with steady finances by scanning the solid balance sheet and fundamentals stocks screener (48 results) built to highlight resilient balance sheets and consistent fundamentals.
• Spot potential bargains early by using the screener containing 19 high quality undiscovered gems that zeroes in on fundamentally strong companies flying under most investors' radar.
• Prioritize sleep-at-night holdings with the 65 resilient stocks with low risk scores designed to surface companies with lower overall risk profiles and more stable characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.